
Opdivo (nivolumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts
Description
Opdivo (nivolumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on opdivo (nivolumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Where is the largest and fastest growing market for opdivo (nivolumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The opdivo (nivolumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Markets Covered:1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL
2) By Dosage: Injection; Solution; Other Dosages
3) By Demographic: Adult; Pediatric
4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
5) By End-User: Hospitals; Clinics; Other End Users
Companies Mentioned: Bristol-Myers Squibb; Ono Pharmaceutical
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
This report focuses on opdivo (nivolumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for opdivo (nivolumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The opdivo (nivolumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Markets Covered:1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL
2) By Dosage: Injection; Solution; Other Dosages
3) By Demographic: Adult; Pediatric
4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
5) By End-User: Hospitals; Clinics; Other End Users
Companies Mentioned: Bristol-Myers Squibb; Ono Pharmaceutical
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Table of Contents
175 Pages
- 1. Executive Summary
- 2. Opdivo (Nivolumab) Market Characteristics
- 3. Opdivo (Nivolumab) Market Biologic Drug Characteristics
- 3.1. Molecule Type
- 3.2. Route Of Administration (ROA)
- 3.3. Mechanism Of Action (MOA)
- 3.4. Safety And Efficacy
- 4. Opdivo (Nivolumab) Market Trends And Strategies
- 5. Opdivo (Nivolumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
- 6. Global Opdivo (Nivolumab) Growth Analysis And Strategic Analysis Framework
- 6.1. Global Opdivo (Nivolumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 6.2. Analysis Of End Use Industries
- 6.3. Global Opdivo (Nivolumab) Market Growth Rate Analysis
- 6.4. Global Opdivo (Nivolumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 6.5. Global Opdivo (Nivolumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 6.6. Global Opdivo (Nivolumab) Total Addressable Market (TAM)
- 7. Global Opdivo (Nivolumab) Market Pricing Analysis & Forecasts
- 8. Opdivo (Nivolumab) Market Segmentation
- 8.1. Global Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 40 mg/4 mL
- 100 mg/10 mL
- 240 mg/24 mL
- 8.2. Global Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Injection
- Solution
- Other Dosages
- 8.3. Global Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Adult
- Pediatric
- 8.4. Global Opdivo (Nivolumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Melanoma
- Non-small Cell Lung Cancer (NSCLC)
- Malignant Pleural Mesothelioma
- Classical Hodgkin Lymphoma (CHL)
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Renal Cell Carcinoma (RCC)
- Other Applications
- 8.5. Global Opdivo (Nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Other End Users
- 9. Global Opdivo (Nivolumab) Market Epidemiology Of Clinical Indications
- 9.1. Drug Side Effects
- 9.2. Incidence And Prevalence of Clinical Indications
- 10. Opdivo (Nivolumab) Market Regional And Country Analysis
- 10.1. Global Opdivo (Nivolumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. Global Opdivo (Nivolumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11. Asia-Pacific Opdivo (Nivolumab) Market
- 11.1. Asia-Pacific Opdivo (Nivolumab) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 11.2. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12. China Opdivo (Nivolumab) Market
- 12.1. China Opdivo (Nivolumab) Market Overview
- 12.2. China Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 12.3. China Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 12.4. China Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 13. India Opdivo (Nivolumab) Market
- 13.1. India Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. India Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. India Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14. Japan Opdivo (Nivolumab) Market
- 14.1. Japan Opdivo (Nivolumab) Market Overview
- 14.2. Japan Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. Japan Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. Japan Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15. Australia Opdivo (Nivolumab) Market
- 15.1. Australia Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.2. Australia Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Australia Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16. South Korea Opdivo (Nivolumab) Market
- 16.1. South Korea Opdivo (Nivolumab) Market Overview
- 16.2. South Korea Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. South Korea Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.4. South Korea Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17. Western Europe Opdivo (Nivolumab) Market
- 17.1. Western Europe Opdivo (Nivolumab) Market Overview
- 17.2. Western Europe Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Western Europe Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.4. Western Europe Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18. UK Opdivo (Nivolumab) Market
- 18.1. UK Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. UK Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. UK Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19. Germany Opdivo (Nivolumab) Market
- 19.1. Germany Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Germany Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Germany Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20. France Opdivo (Nivolumab) Market
- 20.1. France Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. France Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. France Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21. Eastern Europe Opdivo (Nivolumab) Market
- 21.1. Eastern Europe Opdivo (Nivolumab) Market Overview
- 21.2. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22. North America Opdivo (Nivolumab) Market
- 22.1. North America Opdivo (Nivolumab) Market Overview
- 22.2. North America Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. North America Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.4. North America Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23. USA Opdivo (Nivolumab) Market
- 23.1. USA Opdivo (Nivolumab) Market Overview
- 23.2. USA Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. USA Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. USA Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24. Canada Opdivo (Nivolumab) Market
- 24.1. Canada Opdivo (Nivolumab) Market Overview
- 24.2. Canada Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. Canada Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. Canada Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25. South America Opdivo (Nivolumab) Market
- 25.1. South America Opdivo (Nivolumab) Market Overview
- 25.2. South America Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. South America Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. South America Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26. Middle East Opdivo (Nivolumab) Market
- 26.1. Middle East Opdivo (Nivolumab) Market Overview
- 26.2. Middle East Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. Middle East Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. Middle East Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27. Africa Opdivo (Nivolumab) Market
- 27.1. Africa Opdivo (Nivolumab) Market Overview
- 27.2. Africa Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Africa Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.4. Africa Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28. Opdivo (Nivolumab) Market Competitive Landscape And Company Profiles
- 28.1. Opdivo (Nivolumab) Market Competitive Landscape
- 28.2. Opdivo (Nivolumab) Market Company Profiles
- 28.2.1. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
- 28.2.2. Ono Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis
- 29. Global Opdivo (Nivolumab) Market Pipeline Analysis
- 29.1. High Level Clinic Trail Information
- 30. Global Opdivo (Nivolumab) Market Competitive Benchmarking And Dashboard
- 31. Key Mergers And Acquisitions In The Opdivo (Nivolumab) Market
- 32. Recent Developments In The Opdivo (Nivolumab) Market
- 33. Opdivo (Nivolumab) Market High Potential Countries, Segments and Strategies
- 33.1 Opdivo (Nivolumab) Market In 2029 - Countries Offering Most New Opportunities
- 33.2 Opdivo (Nivolumab) Market In 2029 - Segments Offering Most New Opportunities
- 33.3 Opdivo (Nivolumab) Market In 2029 - Growth Strategies
- 33.3.1 Market Trend Based Strategies
- 33.3.2 Competitor Strategies
- 34. Appendix
- 34.1. Abbreviations
- 34.2. Currencies
- 34.3. Historic And Forecast Inflation Rates
- 34.4. Research Inquiries
- 34.5. The Business Research Company
- 34.6. Copyright And Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.